allosteric Pol_ DNA polymerase inhibitor

oral activity in BRCA- xenograft (100 mpk QD)

from 165k cmpd biochem. HTS and opt.

Nature Communications

Artios Pharma, Cambridge / ICR, London, UK

4. The Artios Pharma selective allosteric Pol_ DNA polymerase inhibitor, ART558, induces synthetic lethality in BRCA-mutant cancer cells and enhances PARP inhibitor activity. Defects in the 53BP1/Shieldin complex (which…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.